CD47 and lymphoma: A similar approach was recently published, and the respective SIRPabodies, which combine an antiCD20 mAb and the endogenous SIRPα domain, were shown to bind CD20 and CD47 on dual expressing cells, reduce tumor burden and prolong survival in xenograft lymphoma mouse models [17].